Healthcare Equipment and Supplies
Company Overview of LED Medical Diagnostics Inc.
LED Medical Diagnostics Inc. develops and markets medical devices in the dental industry under the VELscope trade name in North America. Its products include Velscope Vx system, a device for the enhanced visualization of mucosal abnormalities, such as oral cancer and premalignant dysplasia; VELscope Vx imaging adapter for fluorescence and white-light clinical imaging; Vx VELcaps to prevent patient cross contamination; Vx VELsheaths, a single use plastic sheath to prevent patient cross contamination; and Vx Value Bundle, a portable handheld device used to conduct oral tissue examinations. The company also provides diagnostic imaging products and software to dental and oral health specialists....
235–5589 Byrne Road
Burnaby, BC V5J 3J1
Founded in 2003
Key Executives for LED Medical Diagnostics Inc.
Chief Executive Officer and Director
Total Annual Compensation: $278.6K
Director and President of Led Dental Ltd
Total Annual Compensation: $244.9K
Compensation as of Fiscal Year 2015.
LED Medical Diagnostics Inc. Key Developments
LED Medical Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016
Nov 25 16
LED Medical Diagnostics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, net revenue was $2,488,725, which is an increase of 40% from the three months ended September 30, 2015. This revenue increase was largely due to timing of when imaging orders were received and could be shipped and by increased demand for VELscope and VELscope consumable sales. The net loss before tax for the three months ended September 30, 2016 was $855,484 compared to the net loss before taxes for the three months ended September 30, 2015 of $1,361,773. The decrease of operating loss is mainly attributable to higher revenue levels and lower operating expense than in fiscal 2015.
Net revenue for the nine months ended September 30, 2016 was $8.3 million which is an increase of 11% from the prior year period of $7.5 million. Net loss before tax for the nine months ended September 30, 2016 was $3.9 million compared to the net loss before taxes in the prior year period of $4.0 million. The decrease of operating loss is mainly attributable to higher revenue levels and lower operating expense than in fiscal 2015.
Led Medical Diagnostics Inc. Announces e Results of Meta-Analysis on the Clinical Use of Autofluorescence
Nov 17 16
LED Medical Diagnostics Inc. announced the results of a meta-analysis on the clinical use of autofluorescence to assess its accuracy for oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMD) and investigate its applicability in general dental practice. The study by Luo et al titled "Accuracy of Autofluorescence in Diagnosing Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Comparative Study with Aero-Digestive Lesions" was published in Scientific Reports, an online, open access journal from the publishers of Nature. The study was a meta-analysis of previously published data to assess the accuracy of autofluorescence in diagnosing OSCC and OPMD and reported the findings of statistical analyses conducted on 24 previously reported studies detecting OSCC and OPMD in 2761 total lesions. The study reported a pooled sensitivity and specificity of the use of autofluorescence for the detection of OSCC and OPMD of 0.89 and 0.80 respectively and concluded that autofluorescence is a promising, non-invasive tool for the early diagnosis of OSCC and OPMD. The study's authors also remark that using autofluorescence technology as an adjunctive imaging tool may be most reliable in the hands of oral specialists but that the use of promising clinical decision making algorithms could facilitate its adoption in primary care.
LED Medical Diagnostics, Inc. Announces Launch of VELscope Vx Enhanced Oral Assessment System in China
Nov 14 16
LED Medical Diagnostics Inc. announced the availability of the VELscope Vx Enhanced Oral Assessment System in China, marking the expansion of its technology to a key emerging market in one of the world"(TM)s economies. The official launch of the VELscope Vx in China took place in Shanghai in late October during DenTech China, the professional exhibition and symposium event for dental technology in Asia. The VELscope is now available in China exclusively through Prospect Dentech, a subsidiary of SINOPHARM and stomatological medicine and equipment distributor in China. The initial stocking order of VELscope systems has now been delivered with fulfillment of local sales beginning in the coming days. With over 4,000 hospitals and a rapid growth of private dental clinics, China is uniquely suited for adoption of VELscope technology. Prospect Dentech has initiated an aggressive marketing strategy, leveraging their existing distribution and Key Opinion Leader network to educate Chinese clinicians on the proper use of the VELscope"(TM)s tissue fluorescence visualization technology during oral examinations. LED Dental continues to provide sales and training support, recently localizing all VELscope marketing materials and their Apple iPod imaging application into Mandarin.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 21, 2016
July 4, 2016